The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | P | Antiparasitic products, insecticides and repellents | |
| 2 | P01 | Antiprotozoals | |
| 3 | P01B | Antimalarials | |
| 4 | P01BE | Artemisinin and derivatives | |
| 5 | P01BE03 | Artesunate |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.28 g |
| PAREN - Parenteral | 0.28 g |
| Active Ingredient | Description | |
|---|---|---|
| Artesunate |
Artesunate is a semi-synthetic artemisinin derivative, indicated for the initial treatment of severe malaria in adults and children. The antimalarial mechanism of action of artesunate is generally thought to depend upon activation involving iron-mediated cleavage of the endoperoxide bridge of DHA to generate an unstable organic free radical followed by alkylation, where the free radical binds to malarial proteins leading to destruction of parasite membranes. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
